An anti-CD52 monoclonal antibody (alemtuzumab) may be another option as it has been more effective than rituximab in treating idiopathic or secondary PRCA, highlighting the importance of T-cells in PRCA pathophysiology (5, 17). The gene discussed is CD52; the disease is pure red-cell aplasia.